Assignee
CELLA THERAPEUTICS LLC
US·2 granted patents·7 pending applications·4 citations·filing 2019–2025
Top patents by PatentIndex Score
9 records- 0190US11147855B2Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humourCELLA THERAPEUTICS LLC·Filed 2019·Granted Oct 19, 2021·3 cites·19 claims
- 0285US12128104B2Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2020·Granted Oct 29, 2024·1 cites·17 claims
- 0384US2026048097A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 0479US2025090670A1Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 0577US2023158161A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 0675US2026041777A1Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 0774US2022339237A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 0872US2021121534A1Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 0952US2023094423A1Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →